Changes in molecular forms of prostate-specific antigen during treatment with finasteride

BJU International

Volumn 90, Issue 7, 2002, Pages 672-677

  Espana F ^a   Martinez M ^a   Royo, M ^a   Estelles A ^a   Alapont, J M ^a   Navarro, S ^a   Aznar, J ^a   Jimenez Cruz J F ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

BPH; Complexed PSA; Finasteride; Free PSA; Plasma; Serum

Indexed keywords

ALLOANTIGEN; ALPHA 1 ANTICHYMOTRYPSIN; FINASTERIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CHEMICAL STRUCTURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG EFFECT; EARLY DIAGNOSIS; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MALE; PLASMA; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SERUM; STATISTICAL SIGNIFICANCE;

AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FINASTERIDE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA;

EID: 0036432805     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2002.03002.x     Document Type: Article

References (25)

1. Guess HA, Heyse JF, Gormley GJ. The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia. Prostate 1993; 22: 31-7
2. Guess HA, Gormley GJ, Stoner E et al. The effect of finasteride on prostate specific antigen: Review of available data. J Urol 1996; 155: 3-9
3. Gormley GJ, Ny J, Cook T et al. Effect of finasteride on prostate-specific density. Urology 1994; 43: 53-8
4. Oesterling JE, Roy J, Agha A et al. Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: Effects of finasteride. Urology 1997; 50: 13-8
5. Andriole GL, Guess HA, Epstein JI et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: Results of a randomized, double-blind, placebo controlled clinical trial. Urology 1998; 52: 195-202
6. Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990; 194: 755-60
7. 2-macroglobulin complexes in prostate cancer patient sera. Biochem Mol Biol Internat 1995; 37: 917-23
8. 1-antichymotrypsin is the mayor form of prostate-specific antigen in serum of patients with prostate cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51: 222-6
9. 1-antichymotrypsin complexes in serum. Eur J Clin Chem Clin Biochem 1991; 29: 787-94
10. 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993; 150: 100-5
11. 1-antichymotrypsin in the plasma of patients with prostatic disease. Eur Urol 1996; 30: 512-8
12. Schoojans F, Zalata A, Depuydt CE et al. MedCalc: A new computer program for medical statistics. Comput Meth Progr Biomed 1995; 48: 257-63
13. 1-antichymotrypsin in the early detection of prostate cancer. Eur Urol 2000; 38: 85-90
14. Komatsu K, Wehner N, Prestigiacomo AF et al. Physiologic (intraindividual) variation of serum prostate-specific antigen in 814 men from a screening population. Urology 1996; 47: 343-6
15. Catalona WJ, Smith DS, Wolfert RL et al. Evaluation of percentage of free serum prostate specific antigen to improve specificity of prostate cancer screening. JAMA 1995; 274: 1214-20
16. McCormak RT, Rittenhouse HG, Finlay JA et al. Molecular forms of prostate specific antigen and the human kallikrein general family: A new era. Urology 1995; 45: 729-44
17. Partin AW, Catalona WJ, Southwick PC et al. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: Influence of total PSA, prostate volume, and age. Urology 1996; 48: 55-61
18. Vashi AR, Wojno KJ, Henricks W et al. Determination of the (reflex range' and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSym System. Urology 1997; 49: 19-27
19. Bangma CH, Rietbergen JB, Kranse Ret al. The free-to-total prostate specific antigen ratio improves the specificity of prostate cancer in the general population. J Urol 1997; 157: 2191-6
20. 1-antichymotrypsin in blood samples. Urology 1996; 48: 81-7
21. España F, Royo M, Martínez M et al. Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: Studies in serum and plasma samples. J Urol 1998; 160: 2081-8
22. Matzkin H, Barak M, Braf Z. Effect of finasteride on free and total serum prostate-specific antigen in men with benign prostatic hyperplasia. Br J Urol 1996; 78: 405-8
23. Keetch DW, Andriole GL, Ratliff TL et al. Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting. Urology 1997; 50: 901-5
24. Pannek J, Marks LS, Pearson JD et al. Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia. J Urol 1998; 159: 449-53
25. Morote J, Lorente JA, Raventos CX et al. Efecto del finasteride en el porcentaje de PSA libre: Implicaciones en el diagnóstico precoz de cáncer de próstata. Actas Urol Esp 1998; 22: 835-9